Long-term data from the KEYNOTE-010 trial showed that 35% of over 1,000 patients with non-small cell lung cancer (NSCLC) who had progressed on chemotherapy and were then treated…
The Oncologic Drugs Advisory Committee (ODAC) voted 6–5 that combining ramucirumab combined with established first-line EGFR-directed therapy had a favorable risk-benefit profile for patients with metastatic EGFR-mutant non-small…
In this double interview, Ross Camidge, MD, PhD, of the University of Colorado Cancer Center, and Lyudmila A. Bazhenova, MD, of UC San Diego Health, provide insights into…
New techniques and technology advancements in the field of radiation oncology are the topics of discussion in this interview with Amin J. Mirhadi, MD, associate professor of radiation…
In this video, Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology for the Sidney Kimmel Cancer Center at Johns Hopkins Medicine, stresses…
Geoffrey Oxnard, MD, associate professor of medicine at Harvard Medical School, discusses the advancements in treatments for lung cancer over the past 10 to 15 years. Even though…
Heather A. Wakelee, MD, thoracic oncologist and professor of medicine at Stanford University Medical Center, discusses the decisions that go into planning treatments for newly diagnosed, advanced stage…
Lyudmila A. Bazhenova, MD, professor of medicine at UC San Diego Health, discusses the lack of data on chemoimmunotherapy or monotherapy immunotherapy for treatment of ALK-fused non-small cell…
Ashish Saxena, MD, PhD, assistant attending at New York-Presbyterian Hospital and assistant professor of medicine at Weill Cornell Medical College, reviews first-line therapies in non-small cell lung cancer.…